Parathyroid hormone-related protein: Potential therapeutic target for melanoma invasion and metastasis

Endocrinology (United States)

Volumn 155, Issue 10, 2014, Pages 3739-3749

  Huang, Dao Chao ^a   Yang, Xian Fang ^a   Ochietti, Benoît ^a   Fadhil, Ibtihal ^a   Camirand, Anne ^a   Kremer, Richard ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; FOCAL ADHESION KINASE; GELATINASE B; GREEN FLUORESCENT PROTEIN; MONOCLONAL ANTIBODY; PARATHYROID HORMONE RELATED PROTEIN; SMALL INTERFERING RNA;

A375 CELL LINE; ACTIN POLYMERIZATION; AMINO TERMINAL SEQUENCE; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; CANCER SIZE; CANCER SURVIVAL; CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CELL SPREADING; CHEMOTAXIS ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; FOCAL ADHESION; GENE INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG SCREENING; GENE SILENCING; GENETICS; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; SKIN NEOPLASMS; TUMOR CELL CULTURE;

ANIMALS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PARATHYROID HORMONE-RELATED PROTEIN; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907209886     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1803     Document Type: Article

References (50)

1. Miller AJ, Mihm MC. Melanoma. N Engl J Med. 2006;355(1):51-65.
2. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012;12(5):349-361.
3. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21): 2904-2909.
4. Gensure RC, Gardella TJ, Jüppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun. 2005;328(3):666-678.
5. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VL, Kronenberg HM, Mulligan RC. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev. 1994;8(3):277-289.
6. Maioli E, Fortino V. The complexity of parathyroid hormone-related protein signalling. Cell Mol Life Sci. 2004;61(3):257-262.
7. Miao D, Su H, He B, Gao J, Xia Q, Zhu M, Gu Z, Goltzman D, Karaplis AC. Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTHrelated protein. Proc Natl Acad Sci U S A. 2008;105(51):20309-20314.
8. Philbrick WM, Dreyer BE, Nakchbandi IA, Karaplis AC. Parathyroid hormone-related protein is required for tooth eruption. Proc Natl Acad Sci U S A. 1998;95(20):11846-11851.
9. Wysolmerski JJ, PhilbrickWM,Dunbar ME, Lanske B, Kronenberg H, Broadus AE. Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. Development. 1998;125(7):1285-1294.
10. Brandt DW, Burton DW, Gazdar AF, Oie HE, Deftos LJ. All major lung cancer cell types produce parathyroid hormone-like protein: heterogeneity assessed by high performance liquid chromatography. Endocrinology. 1991;129(5):2466-2470.
11. Bucht E, Rong H, Pernow Y, et al. Parathyroid Hormone-related protein in patients with primary breast cancer and eucalcemia. Cancer Res. 1998;58(18):4113-4116.
12. Kitazawa S, Takenaka A, Gotoh A, et al. Immunohistologic evaluation of parathyroid hormone-related protein in human lung cancer and normal tissue with newly developed monoclonal antibody. Cancer. 1991;67(4):984-989.
13. Kohno N, Kitazawa S, Fukase M, et al. The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surg Today. 1994;24(3):215-220.
14. Dougherty KM, Blomme EA, Koh AJ, et al. Parathyroid hormonerelated protein as a growth regulator of prostate carcinoma. Cancer Res. 1999;59(23):6015-6022.
15. Nishigaki Y, Ohsaki Y, Toyoshima E, Kikuchi K. Increased serum and urinary levels of a parathyroid hormone-related proteinCOOH terminus in non-small cell lung cancer patients. Clin Cancer Res. 1999;5(6):1473-1481.
16. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584-593.
17. Mundy GR, Edwards JR. PTH-Related Peptide (PTHrP) in Hypercalcemia. J Am Soc Nephrol. 2008;19(4):672-675.
18. Li J, Karaplis AC, Huang DC, Siegel PM, Camirand A, Yang XF, Muller WJ, Kremer R. PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest. 2011;121(12):4655-4669.
19. Kageshita T, Matsui T, Hirai S, Fukuda Y, Ono T. Hypercalcaemia in melanoma patients associated with increased levels of parathyroid hormone-related protein. Melanoma Res. 1999;9(1):69-73.
20. Maruta S, Takiguchi S, Ueyama M, et al. A role for leukemia inhibitory factor in melanoma-induced bone metastasis. Clin Exp Metastasis. 2009;26(2):133-141.
21. Kageshita T, Ishihara T, Tokuo H, et al. Widespread expression of parathyroid hormone-related peptide in melanocytic cells. Br J Dermatol. 2003;148(3):533-538.
22. El Abdaimi K, Papavasiliou V, Goltzman D, Kremer R. Expression and regulation of parathyroid hormone-related peptide in normal and malignant melanocytes. Am J Physiol Cell Physiol. 2000; 279(4):C1230-C1238.
23. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004;23(37):6292-6298.
24. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 1984;44(8):3522-3529.
25. Hauck CR, Hsia DA, Puente XS, Cheresh DA, Schlaepfer DD. FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J. 2002; 21(23):6289-6302.
26. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362-374.
27. Narla RK, Liu XP, Klis D, Uckun FM. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3-bromo-4-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). Clin Cancer Res. 1998;4(10):2463-2471.
28. Roeb E, Schleinkofer K, Kernebeck T, et al. The matrix metalloproteinase 9 (MMP-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem. 2002;277(52): 50326-50332.
29. El Abdaimi K, Dion N, Papavasiliou V, et al. The vitaminDanalogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 2000;60(16):4412-4418.
30. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol. 1994;14(3):1680-1688.
31. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 2012; 1825(1):29-36.
32. MohammadKS, Javelaud D, Fournier PG, et al. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 2011;71(1):175-184.
33. Yeung SC, Eton O, Burton DW, Deftos LJ, Vassilopoulou-Sellin R, Gagel RF. Hypercalcemia due to parathyroid hormone-related protein secretion by melanoma. Horm Res. 1998;49(6):288-291.
34. PartinAW,Schoeniger JS, Mohler JL, Coffey DS. Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A. 1989;86(4):1254-1258.
35. McClelland P, Onyia JE, Miles RR, et al. Intermittent administration of parathyroid hormone (1-34) stimulates matrix metalloproteinase-9 (MMP-9) expression in rat long bone. J Cell Biochem. 1998;70(3):391-401.
36. Machesky LM, Hall A. Role of actin polymerization and adhesion to extracellular matrix in Rac-and Rho-induced cytoskeletal reorganization. J Cell Biol. 1997;138(4):913-926.
37. Schwarzbauer JE. Cell migration: May the force be with you. Curr Biol. 1997;7(5):R292-R294.
38. Shen X, Falzon M. Parathyroid hormone-related protein upregulates integrin expression via an intracrine pathway in PC-3 prostate cancer cells. Regul Pept. 2003;113(1):17-29.
39. Shen X, Rychahou PG, Evers BM, Falzon M. PTHrP increases xenograft growth and promotes integrin 64 expression and Akt activation in colon cancer. Cancer Lett. 2007;258(2):241-252.
40. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18(5):516-523.
41. Chen HC, Appeddu PA, Isoda H, Guan JL. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J Biol Chem. 1996;271(42):26329-26334.
42. Oktay M, Wary KK, Dans M, Birge RB, Giancotti FG. Integrinmediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. The J Cell Biol. 1999;145(7):1461-1469.
43. Henderson JE, Amizuka N, Warshawsky H, et al. Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol. 1995;15(8):4064-4075.
44. Fogelquist S, Deutsch B, Groszek L, Valle EF, Stackpole C. Hemodynamic considerations in organ and tissue patterning of B16 melanoma systemic metastasis and colonization. Invasion Metastasis. 1991;11:261-272.
45. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133(3421):571-573.
46. Roodman G. Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev. 2012;31(3):569-578.
47. Haq M, Kremer R, Goltzman D, Rabbani SA.AvitaminDanalogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest. 1993;91(6):2416-2422.
48. Bhatia V, Saini MK, Shen X, et al. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther. 2009; 8(7):1787-1798.
49. Talon I, Lindner V, Sourbier C, et al. Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo. Carcinogenesis. 2006;27(1):73-83.
50. Iguchi H, Tanaka S, Ozawa Y, et al. An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. Cancer Res. 1996;56(17): 4040-4043.